Derbyshire Medicines Management
and Clinical Policies
GREY by exceptionality defined as intolerance to the preferred 1st line choice (Lixisenatide) or restricted by their licensing. See local guidance for supporting material for prescribers.
RED: NICE TA664 - Liraglutide (Saxenda) for managing overweight and obesity. Liraglutide is recommended as an option for managing overweight and obesity alongside a reduced-calorie diet and increased physical activity in adults, but it is restricted to prescribing in secondary care by a specialist multidisciplinary tier 3 weight management service with a commercial agreement in place. (Decision date - January 2021)
